<DOC>
	<DOC>NCT01111968</DOC>
	<brief_summary>This is a prospective phase I study to evaluate the safety, tolerability and immunogenicity of nine adjuvanted candidate vaccines against pandemic influenza A (H1N1) virus.</brief_summary>
	<brief_title>Evaluation of Pandemic Influenza A (H1N1)Candidate Vaccines</brief_title>
	<detailed_description>The candidate vaccines are produced by Butantan institute - Sao Paulo, Brazil</detailed_description>
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Health adults of both genders Age ≥ 18 ≤ 50 years Able to understand every required study procedure Female volunteers should agree to take an acceptable contraceptive method Menopause is characterized by absence of menstrual flux for two consective years Normal values for prestablished laboratory assays Accpetance to participate and sign the consent form Any chronic condition Be on immunossupressive or stimulant therapy Have egg alergy Have past history of alergy to sazonal influenza vaccine Have received another inactivated vaccine within the prior 2 weeks or a live vaccine in the past four weeks to his/her participation in the study Acute infectious disease during seven days prior vaccination Female on breasthfeeding Confirmed prior infection by pandemic influenza A Participation in another clinical trial in the last 6 months Any other condition identified by the principal investigator which is considered not safe for enrollment of the volunteer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>vaccine</keyword>
	<keyword>pandemic influenza A</keyword>
	<keyword>adjuvant</keyword>
	<keyword>safety</keyword>
</DOC>